MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$4,014,794
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from issuance of equity...
Equity-based compensation expens...
Accrued expenses and other curre...
Depreciation and amortization
Negative Cash Flow Breakdown
Net loss
Prepaid expenses and other asset...
Accounts payable
Short term promissory note
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-09-30
2025-06-30
Net loss
-873,467
-2,667,358
Depreciation and amortization
1,106
2,212
Equity-based compensation expense
22,846
56,689
Prepaid expenses and other assets
490,565
11,659
Accounts payable
-310,839
337,971
Accrued expenses and other current liabilities
4,230
238,134
Net cash used in operating activities
-1,646,689
-2,044,011
Short term promissory note
200,000
-
Net cash used in investing activities
-200,000
-
Proceeds from issuance of equity securities, net
5,861,483
626,235
Payments on note payable
0
221,866
Net cash provided by (used in) provided by financing activities
5,861,483
404,369
Net decrease in cash and cash equivalents
4,014,794
-1,639,642
Cash and cash equivalents at beginning of period
2,434,528
-
Cash and cash equivalents at end of period
4,809,680
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
equity securities, net
$5,861,483
Net cash provided by
(used in) provided by...
$5,861,483
Net decrease in cash
and cash...
$4,014,794
Canceled cashflow
$1,846,689
Equity-based compensation
expense
$22,846
Accrued expenses and
other current...
$4,230
Depreciation and
amortization
$1,106
Net cash used in
operating activities
-$1,646,689
Net cash used in
investing activities
-$200,000
Canceled cashflow
$28,182
Net loss
-$873,467
Prepaid expenses and
other assets
$490,565
Accounts payable
-$310,839
Short term promissory
note
$200,000
Buy us a coffee
Salarius Pharmaceuticals, Inc. (SLRX)
Salarius Pharmaceuticals, Inc. (SLRX)